Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 30, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Visa Inc. (V - Free Report) , Eli Lilly and Company (LLY - Free Report) , Amgen Inc. (AMGN - Free Report) and Sony Group Corporation (SONY - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

Top Analyst Reports for Alphabet, Visa and Eli Lilly

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet, Visa and Eli Lilly. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Shares of Alphabet have outperformed the S&P 500 in the year-to-date period (+39.8% vs. +15.8%). The Zacks analyst believes that expanding data centers will continue to bolster the company's presence in the cloud space. Further, major updates in its search segment are enhancing the search results.

Moreover, strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Also, the company's growing efforts to gain a foothold in the healthcare industry are other positives. However, its growing litigation issues and increasing expenses remain concerns.

(You can read the full research report on Alphabet here >>>)

Visa's shares have gained +7.7% over the last six months against the Zacks Financial Transaction Services industry's gain of +2.5%. The Zacks analyst believes that numerous acquisitions and alliances have paved the way for long-term growth and consistently drove Visa's revenues. It continues to invest in technology to further boost its already leading position in the payments market.

Further, the coronavirus vaccine development and the gradual revival of consumer confidence will drive spending, expanding business volumes in turn. However, high operating expenses stress the operating margins. Also, ramped-up client initiatives are likely to dent the top line.

(You can read the full research report on Visa here >>>)

Shares of Eli Lilly have gained +23.6% in the past three months against the Zacks Large Cap Pharmaceuticals industry's gain of +9.6%. The Zacks analyst believes that Lilly's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, among others.

The company's pipeline assets for cancer, diabetes and Alzheimer's are likely to keep supporting its growth well beyond 2025. It also received rapid emergency approvals for COVID-19 antibody cocktail drugs. However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Other noteworthy reports we are featuring today include Amgen and Sony Group.

+1,500% Growth: One of 2021's Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks' top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things's exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.